Home>Topics>Companies>GlaxoSmithKline

GlaxoSmithKline

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
  1. India's Cipla launches copy of GSK's top asthma drug in Germany, Sweden

    Headlines

    Mon, 1 Sep 2014

    MUMBAI, Sept 1 (Reuters) - India's Cipla Ltd has launched an anti-asthma inhaler in Germany and Sweden that is a generic version of GlaxoSmithKline Plc 's Advair, a move that will further dent sales of the British firm's top-selling product.

  2. Is GlaxoSmithKline A Solid Long-Term Investment?

    Headlines

    Fri, 29 Aug 2014

    index as well as the healthcare sector. However, GlaxoSmithKline (NYSE: GSK ) has been suffering due to some issues in China and ..... again due to recent FDA drug approvals. Moreover, GSK 's deal with Novartis (NYSE: NVS ) has improved

  3. AbbVie: Growth Story Or Patent Expiration Nightmare?

    Headlines

    Thu, 28 Aug 2014

    largest publicly traded drug manufacturer in the world, behind giants such as AstraZeneca (NYSE: AZN ), GlaxoSmithKline (NYSE: GSK ), and Pfizer (NYSE: PFE ). Humira Is AbbVie's Biggest Winner AbbVie generated 67% of its 2nd-quarter

  4. Gilead: Let's Make A Deal

    Headlines

    Thu, 28 Aug 2014

    market cap) than many familiar pharma names including Sanofi, Lilly, AbbVie, Bayer AG, Bristol-Myers-Squibb, GlaxoSmithKline , AstraZeneca, Novo Nordisk, and Amgen. Gilead is rapidly approaching the market cap of the two largest US pure

  5. Ebola cases accelerating

    Headlines

    Thu, 28 Aug 2014

    Ebola Vaccine in Preclinicals; BioCryst Pharmaceuticals (NASDAQ: BCRX ): BCX4430 in Preclinicals; GlaxoSmithKline (NYSE: GSK ): Ebola Vaccine in Preclinicals; Nanoviricides (NYSEMKT: NNVC ): NV-INF-1 in Preclinicals; Inovio

  6. GSK Ebola vaccine fast-tracked into U.S., UK and African trials

    Headlines

    Thu, 28 Aug 2014

    LONDON, Aug 28 (Reuters) - An experimental Ebola vaccine from GlaxoSmithKline is being fast-tracked into human studies and the company plans to build up a stockpile of up to 10,000 doses for emergency deployment, if results are good.

  7. Glaxo's ebola vaccine to begin human clinical trials shortly

    Headlines

    Thu, 28 Aug 2014

    announcement by U.S. health officials today will state that a human study for the Ebola vaccine made by GlaxoSmithKline (NYSE: GSK ) will begin within a couple of weeks instead of later this year as the company originally estimated. Glaxo

  8. Ebola vaccine from GSK to begin U.S. clinical trials within weeks-sources

    Headlines

    Wed, 27 Aug 2014

    27 (Reuters) - U.S. health officials will announce on Thursday that a human study of an Ebola vaccine made by GlaxoSmithKline will begin within a couple of weeks and not later this year as the company estimated originally, according to people

  9. Tekmira +4% on takeover rumors; Shire, Glaxo said to have interest

    Headlines

    Wed, 27 Aug 2014

    treatment for the deadly ebola virus. Rumors suggest interested parties could include Shire (NASDAQ: SHPG ) and GlaxoSmithKline (NYSE: GSK ); the report suggests the recent premium paid for InterMune could put a valuation of at least $40/share

  10. Novo Nordisk: The Case For Predictability In Earnings

    Headlines

    Tue, 26 Aug 2014

    diabetes care market. With the share price up more than 20% year-to-date, Novo Nordisk has now surpassed GlaxoSmithKline (NYSE: GSK ) in market capitalization. The short story about earnings Over the past ten years, Novo Nordisk's annualized

« Prev12345Next »
Content Partners